Appeal No. 2000-1024 Page 3
Application No. 08/379,551
European Patent Applications
Holy et al. (Holy (EP)) 0 253 412 Jul. 18, 1986
Webb, II (Webb (EP)) 0 269 847 Jun. 08, 1988
Yu et al. (Yu (EP)) 0 452 935 Oct. 23, 1991
Starrett et al. (Starrett) 0 481 214 Apr. 22, 1992
Karrer, Organic Chemistry, 2nd English Edition, pp. 92-102 (1946)
The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 11th
Edition, Article No. 7868, p. 1247 (1989)
In addition, appellants rely upon the following references:
DeClercq et al. (DeClercq), “Antiviral activity of phosphonylmethoxyalkyl
derivatives of purine and pyrimidines,” Antiviral Research, Vol. 8, pp. 261-272
(1987)
Holy et al. (Holy (1989)), ”Phosphonylmethyl Ethers of Nucleosides and Their
Acyclic Analogues,” ACS Symposium Series, Vol. 401, pp. 51-71 (1989)
Claims 1, 4, 6, 8, 45-48, 55, 63, 65, 70, 72, 73, 75, 85, 91, 93 and 94
stand rejected under 35 U.S.C. § 103(a) as being obvious over the combination
of Holy (US), Webb (EP or US), Yu (US or EP), Starrett, Holy (EP) and Karrer.
Claims 12-19 stand rejected under 35 U.S.C. § 103(a) as being obvious over the
combination of Holy (US), Holy (EP), Webb (EP or US), Vemishetti, Alexander,
Yu (US or EP) and the Merck Index. Claims 1, 4, 6, 8, 45-48, 55, 63, 65, 70, 72,
73, 75, 85, 91, 93 and 94 stand rejected under the judicially created doctrine of
obviousness-type double patenting over the claims of Holy (US), U.S. Patent No.
4,808,716 (the ’716 patent) as combined with Yu (EP or US), Holy (EP), Starrett
and Karrer. Claims 1, 4, 6, 8, 45-48, 55, 63, 65, 72, 73, 75, 85, 91, 93 and 94
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007